Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
- PMID: 15499118
- PMCID: PMC524116
- DOI: 10.1136/bmj.329.7472.972
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
Abstract
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?
Figures
References
-
- Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Printing Service, 1992. www.health.gov.au/pbs/pharm/pubs/guidelines/content.htm (accessed 5 May 2004).
-
- Ontario Drug Benefits Program. Ontario guidelines for drug submission and evaluation. www.health.gov.on.ca/english/providers/pub/drugs/dsguide/dsguide_mn.html (accessed 1 May 2004).
-
- Hutton J, Maynard A. A NICE challenge for health economics. Health Economics 2000;9: 89-93. - PubMed
-
- Benjamin I, Poston G, Sherlock D. Is the NICE process flawed? Lancet 2002;359: 2120. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources